statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cardiol Therapeutics (CRDL Research Report), Paragon 28...

Analysts Offer Insights on Healthcare Companies: Cardiol Therapeutics (CRDL), Paragon 28 (FNA) and Intra-Cellular Therapies (ITCI)

Cardiol Therapeutics Inc. (TSE:CRDL) has released an update. Cardiol Therapeutics Inc. has made significant strides by completing patient enrollmen...

Cardiol Therapeutics Progresses in Heart Disease Trials

Completed patient enrollment in the Phase II MAvERIC-Pilot study evaluating CardiolRx in patients withrecurrent pericarditis, with topline results expected in Q2 2024CardiolRx granted...

Cardiol Therapeutics Announces Year-End 2023 Update on Operations

InvestorPlace - Stock Market News, Stock Advice & Trading Tips
CRDL stock results show that Cardiol Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.
The post...

CRDL Stock Earnings: Cardiol Therapeutics Beats EPS for Q4 2023

Cardiol Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference Transcript

Cardiol Therapeutics Inc at Emerging Growth Conference Transcript

Cardiol Therapeutics Inc at Canaccord Genuity Growth Conference Transcript

Topline Results Expected in Q2 2024This is a Designated News Release.Toronto, Ontario--(Newsfile Corp. - February 21, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ('Cardiol' or the...

Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis

Designation Based on Pre-Clinical Data and Initial Clinical Data from the Company's MAvERIC-Pilot Phase II StudyThis is a Designated News Release.Toronto, Ontario--(Newsfile Corp. - February 15...

Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis

Toronto, Ontario--(Newsfile Corp. - January 24, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ('Cardiol' or the 'Company'), a clinical-stage life sciences company focused on the...

Cardiol Therapeutics Regains Compliance with all Applicable Listing Standards of The Nasdaq Capital Market

Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on the research and clinical of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. The firm is conducting clinical studies to evaluate the efficacy and safety of CardiolRx in diseases affecting the heart: a Phase II multi-national, randomized, double-blind, placebo-controlled trial (the ARCHER trial) in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis. It is also involved in developing a novel subcutaneously administered drug formulation of cannabidiol intended for use in heart failure. The company was founded by David Elsley, Eldon Smith, and Anthony Bolton on January 19, 2017 and is headquartered in Oakville, Canada.

Volume	200,166.00
52-Wk High	$2.17
52-Wk Low	$0.55

Period	Estimated	Reported	Surprise	Result
Q1'24	-$0.09	--	--	N/A
Q4'23	-$0.09	--	--	N/A
Q3'23	-$0.09	-$0.07	24.51%	BEAT
Q2'23	-$0.09	-$0.09	3.80%	BEAT
Q1'23	-$0.08	-$0.08	0.03%	BEAT

CRDL Cardiol Therapeutics Inc - Ordinary Shares - Class A

About

Feed

News

Earnings

Fundamentals